FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090045924> ?p ?o ?g. }

• W2090045924 endingPage "4422" @default.
• W2090045924 startingPage "4421" @default.
• W2090045924 abstract "Recently, it was reported that sera from healthy volunteers given atovaquone-proguanil (Malarone) inhibited parasite transmission and asexual blood stage development for up to 6 weeks after treatment (1). The lengthy persistence of drug activity was quite unexpected because earlier studies had shown that proguanil and atovaquone had elimination half-lives of about 14 to 20 h (2-4, 10, 11) and 2 to 3 days, (5, 9-11), respectively. This drug combination acts synergistically against malaria parasites and avoids the rapid selection of atovaquone-resistant parasites whenever parasites are exposed to the action of atovaquone alone (7).The present study was designed to quantitate the persistence of atovaquone in three Caucasian volunteers who had participated in a study to assess the effects of repeated subclinical infections on the development of immunity to Plasmodium falciparum (8). The three volunteers (mean weight, 84.8 ± 21.9 kg) had been inoculated intravenously with about 30 parasitized erythrocytes of P. falciparum (3D7 strain) on three occasions at 35-day intervals, and on each occasion, treatment with atovaquone-proguanil (1,000 mg atovaquone-400 mg proguanil daily for 3 days) was started 8 days later. Blood samples were collected at 6, 20, and 35 days after the onset of treatment (Fig. ​(Fig.1).1). None of the volunteers developed symptoms of malaria.FIG. 1. Mean plasma atovaquone (ATQ) concentrations versus time after repeated atovaquone-proguanil treatment for uncomplicated Plasmodium falciparum malaria in three volunteers infected on three occasions. Plasma ATQ concentrations were measured by HPLC (•) ...Mean plasma atovaquone concentrations-versus-time curves measured by high-pressure liquid chromatography (HPLC) (9) were similar after each treatment with atovaquone-proguanil (Fig. ​(Fig.1).1). Comparable values were obtained by bioassay of samples using the 3D7 atovaquone-sensitive strain (6). The average elimination half-life of atovaquone in the three volunteers was 5.9 days by HPLC and 4.9 days by bioassay. The prolonged persistence of atovaquone was further illustrated by the complete suppression of schizont formation when plasma collected up to 35 days after treatment was incubated with parasites of the 3D7 strain (50% inhibitory concentration [IC50], ∼2 ng/ml). In contrast, plasma collected 6 days after treatment failed to inhibit the maturation of parasites of three atovaquone-resistant strains (TM90-C2b, TM91-C32b, TM93-C1088), with mean IC50 values exceeding 4,000 ng/ml (7). These findings suggest that residual atovaquone may have contributed to the suppression of malaria in the volunteers challenged with the 3D7 strain 35 days after treatment (8).The lengthy 5- to 6-day elimination half-life of atovaquone in these three Caucasian volunteers is twice as long as observed previously in African and Asian patients treated with atovaquone (5, 10, 11). Although proguanil concentrations were not measured in this study, numerous previous studies have shown that proguanil and its cycloguanil metabolite are eliminated much more quickly than atovaquone (2-4, 10, 11), and none would be present within a week after atovaquone-proguanil treatment to potentiate the antimalarial activity of atovaquone. The prolonged presence of atovaquone is of little concern as long as this expensive drug continues to be used mainly by travelers to malarious areas. However, if atovaquone-proguanil were used more widely by expatriate residents living in areas of endemicity, long-lasting low atovaquone concentrations in the absence of any residual proguanil may facilitate the rapid selection of atovaquone-resistant parasites." @default.
• W2090045924 created "2016-06-24" @default.
• W2090045924 creator A5003204240 @default.
• W2090045924 creator A5027376307 @default.
• W2090045924 creator A5035536310 @default.
• W2090045924 creator A5062737096 @default.
• W2090045924 creator A5072638559 @default.
• W2090045924 creator A5072651200 @default.
• W2090045924 creator A5082171943 @default.
• W2090045924 date "2005-10-01" @default.
• W2090045924 modified "2023-09-23" @default.
• W2090045924 title "Lengthy Antimalarial Activity of Atovaquone in Human Plasma following Atovaquone-Proguanil Administration" @default.
• W2090045924 cites W1935016814 @default.
• W2090045924 cites W1996353358 @default.
• W2090045924 cites W2038366568 @default.
• W2090045924 cites W2046836167 @default.
• W2090045924 cites W2059702118 @default.
• W2090045924 cites W2100309118 @default.
• W2090045924 cites W2145521440 @default.
• W2090045924 cites W2155973203 @default.
• W2090045924 cites W2398619605 @default.
• W2090045924 cites W2411193364 @default.
• W2090045924 cites W4323053697 @default.
• W2090045924 cites W1901115492 @default.
• W2090045924 doi "https://doi.org/10.1128/aac.49.10.4421-4422.2005" @default.
• W2090045924 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1251540" @default.
• W2090045924 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16189139" @default.
• W2090045924 hasPublicationYear "2005" @default.
• W2090045924 type Work @default.
• W2090045924 sameAs 2090045924 @default.
• W2090045924 citedByCount "63" @default.
• W2090045924 countsByYear W20900459242012 @default.
• W2090045924 countsByYear W20900459242013 @default.
• W2090045924 countsByYear W20900459242014 @default.
• W2090045924 countsByYear W20900459242015 @default.
• W2090045924 countsByYear W20900459242016 @default.
• W2090045924 countsByYear W20900459242017 @default.
• W2090045924 countsByYear W20900459242018 @default.
• W2090045924 countsByYear W20900459242019 @default.
• W2090045924 countsByYear W20900459242020 @default.
• W2090045924 countsByYear W20900459242021 @default.
• W2090045924 countsByYear W20900459242022 @default.
• W2090045924 countsByYear W20900459242023 @default.
• W2090045924 crossrefType "journal-article" @default.
• W2090045924 hasAuthorship W2090045924A5003204240 @default.
• W2090045924 hasAuthorship W2090045924A5027376307 @default.
• W2090045924 hasAuthorship W2090045924A5035536310 @default.
• W2090045924 hasAuthorship W2090045924A5062737096 @default.
• W2090045924 hasAuthorship W2090045924A5072638559 @default.
• W2090045924 hasAuthorship W2090045924A5072651200 @default.
• W2090045924 hasAuthorship W2090045924A5082171943 @default.
• W2090045924 hasBestOaLocation W20900459242 @default.
• W2090045924 hasConcept C112705442 @default.
• W2090045924 hasConcept C17744445 @default.
• W2090045924 hasConcept C185592680 @default.
• W2090045924 hasConcept C199539241 @default.
• W2090045924 hasConcept C203014093 @default.
• W2090045924 hasConcept C2778048844 @default.
• W2090045924 hasConcept C2778371730 @default.
• W2090045924 hasConcept C2779124865 @default.
• W2090045924 hasConcept C2779636613 @default.
• W2090045924 hasConcept C2780765947 @default.
• W2090045924 hasConcept C3020134792 @default.
• W2090045924 hasConcept C43617362 @default.
• W2090045924 hasConcept C71924100 @default.
• W2090045924 hasConcept C98274493 @default.
• W2090045924 hasConceptScore W2090045924C112705442 @default.
• W2090045924 hasConceptScore W2090045924C17744445 @default.
• W2090045924 hasConceptScore W2090045924C185592680 @default.
• W2090045924 hasConceptScore W2090045924C199539241 @default.
• W2090045924 hasConceptScore W2090045924C203014093 @default.
• W2090045924 hasConceptScore W2090045924C2778048844 @default.
• W2090045924 hasConceptScore W2090045924C2778371730 @default.
• W2090045924 hasConceptScore W2090045924C2779124865 @default.
• W2090045924 hasConceptScore W2090045924C2779636613 @default.
• W2090045924 hasConceptScore W2090045924C2780765947 @default.
• W2090045924 hasConceptScore W2090045924C3020134792 @default.
• W2090045924 hasConceptScore W2090045924C43617362 @default.
• W2090045924 hasConceptScore W2090045924C71924100 @default.
• W2090045924 hasConceptScore W2090045924C98274493 @default.
• W2090045924 hasIssue "10" @default.
• W2090045924 hasLocation W20900459241 @default.
• W2090045924 hasLocation W20900459242 @default.
• W2090045924 hasLocation W20900459243 @default.
• W2090045924 hasLocation W20900459244 @default.
• W2090045924 hasOpenAccess W2090045924 @default.
• W2090045924 hasPrimaryLocation W20900459241 @default.
• W2090045924 hasRelatedWork W1901559508 @default.
• W2090045924 hasRelatedWork W1962039507 @default.
• W2090045924 hasRelatedWork W2000230526 @default.
• W2090045924 hasRelatedWork W2007374716 @default.
• W2090045924 hasRelatedWork W2016307598 @default.
• W2090045924 hasRelatedWork W2156134301 @default.
• W2090045924 hasRelatedWork W2164770436 @default.
• W2090045924 hasRelatedWork W2168903926 @default.
• W2090045924 hasRelatedWork W2805546692 @default.
• W2090045924 hasRelatedWork W3093189850 @default.
• W2090045924 hasVolume "49" @default.

• next